Participant flow21

How many started, completed or left each group, period by period.

1 to 20 of 21

Period	Milestone	Group	Participants
Overall Study	STARTED	Trastuzumab Plus Pertuzumab	357
Overall Study	STARTED	Atezolizumab	175
Overall Study	STARTED	Vemurafenib	55
Overall Study	STARTED	Vemurafenib Plus Cobimetinib	15
Overall Study	STARTED	Vismodegib	37
Overall Study	STARTED	Alectinib	21
Overall Study	STARTED	Erlotinib	13
Overall Study	COMPLETED	Trastuzumab Plus Pertuzumab	28
Overall Study	COMPLETED	Atezolizumab	24
Overall Study	COMPLETED	Vemurafenib	3
Overall Study	COMPLETED	Vemurafenib Plus Cobimetinib	0
Overall Study	COMPLETED	Vismodegib	3
Overall Study	COMPLETED	Alectinib	0
Overall Study	COMPLETED	Erlotinib	0
Overall Study	NOT COMPLETED	Trastuzumab Plus Pertuzumab	329
Overall Study	NOT COMPLETED	Atezolizumab	151
Overall Study	NOT COMPLETED	Vemurafenib	52
Overall Study	NOT COMPLETED	Vemurafenib Plus Cobimetinib	15
Overall Study	NOT COMPLETED	Vismodegib	34
Overall Study	NOT COMPLETED	Alectinib	21

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02091141/flow